Ivan Pavlovic

Ivan Pavlovic

Auto-generated profile, based on publicly available information

Ivan Pavlovic

Translational Neurology, Department of Medical Sciences Uppsala University Uppsala Sweden

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
IPIvan Pavlovic
Ivan Pavlovic
CZChristina Zjukovskaja
Christina Zjukovskaja
FNFaisal Hayat Nazir
Faisal Hayat Nazir
MMMalin Müller
Malin Müller
AWAnna Wiberg
Anna Wiberg
JBJoachim Burman
Joachim Burman
Mitochondrial DNA (mtDNA) is a pro-inflammatory damage-associated molecular pattern molecule and could be an early indicator for inflammation and disease activity in MS. Autologous hematopoietic stem cell transplantation (aHSCT) is a potent treatment for MS, but its impact on mtDNA levels in cerebrospinal fluid (CSF) remains unexplored. To verify elevated CSF mtDNA concentrations in MS patients and assess the impact of aHSCT on mtDNA concentrations. Multiplex droplet digital PCR (ddPCR) was used to quantify mtDNA and nuclear DNA in 182 CSF samples. These samples were collected from 48 MS patients, both pre- and post-aHSCT, over annual follow-ups, and from 32 healthy controls. CSF ccf-mtDNA levels were higher in patients with MS, correlated to multiple clinical and analytical factors and were normalized after intervention with aHSCT. Differences before aHSCT were observed with regard to MRI-lesions, prior treatment and number of relapses in the last year prior to aHSCT. Our findings demonstrate elevated CSF mtDNA levels in MS patients, which correlate with disease activity and normalize following aHSCT. These results position mtDNA as a potential biomarker for monitoring inflammatory activity and response to treatment in MS.

1 January 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
IPIvan Pavlovic
Ivan Pavlovic
FAFredrik Axling
Fredrik Axling
FNFaisal Hayat Nazir
Faisal Hayat Nazir
MMMalin Müller
Malin Müller
AWAnna Wiberg
Anna Wiberg
JBJoachim Burman
Joachim Burman
MicroRNAs (miRNAs) are regulators of gene expression and have been reported to be dysregulated in people with multiple sclerosis (pwMS). Autologous hematopoietic stem cell transplantation (aHSCT) is an immune-ablative treatment intervention for pwMS. Currently, it is unknown if aHSCT affects expression levels of miRNAs in CSF. We explored the ability of circulating miRNA to discriminate between pwMS and healthy controls (HCs) and investigated whether these miRNAs were affected by treatment with aHSCT. Using quantitative reverse transcription PCR, 87 miRNAs were analyzed in CSF samples of a discovery cohort (baseline: 4 & HC: 4). The top 22 miRNAs discriminating between pwMS and HCs were then analyzed in 187 CSF samples of a validation cohort (pwMS: 50, HC: 32). Samples, failing quality control or being follow-ups to baseline samples with quality control issues, were excluded from further analyses. The remaining 133 samples (HC: 29, MS: baseline: 33, 1 year: 30, 2 years: 26, 3-5 years: 15) were analyzed for expression of the top 22 miRNAs. Twelve miRNAs were dysregulated in pwMS compared with HC (q < 0.05). Associations with clinical and analytical parameters were observed in relation to all 12 miRNAs; however, a cluster of 4 miRNAs (miR-16-5p, miR-21-5p, miR-150-5p, and miR-146a-5p) with strong correlations (r > 0.60, p < 0.001) with multiple parameters was identified. Of the 12 miRNAs, 8 were differentially expressed in pwMS with gadolinium-enhancing lesions at baseline and 4 by prior disease-modifying treatment class (p < 0.05). These 4 miRNAs correlated strongly with each other, decreased after aHSCT, and remained low throughout the follow-up period (p < 0.05). Target and pathway analysis of these revealed association with biological processes affecting cytokine production, inflammatory response, and regulation of myelin maintenance. miRNAs are dysregulated in CSF from pwMS and particularly in patients with less effective treatments and/or higher inflammatory disease activity. A 4-miRNA signature with elevated expression of miR-16-5p, miR-21-5p, miR-150-5p, and miR-146a-5p was recurring in multiple analyses. After intervention with aHSCT, the expression levels approached the levels of the HCs, suggesting a potent treatment effect.

14 October 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
IPIvan Pavlovic
Ivan Pavlovic
IEIda Erngren
Ida Erngren
KKKim Kultima
Kim Kultima
ALAnders Larsson
Anders Larsson
MMMalin Müller
Malin Müller
JBJoachim Burman
Joachim Burman
Objectives: To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS), and to assess their changes following autologous hematopoietic stem cell transplantation (aHSCT). Methods: CSF samples from pwMS treated with aHSCT ( n = 43) and healthy controls ( n = 32) were analyzed for MMP‐9, TIMP‐1, and OPN concentrations using ELISA and electrochemiluminescence assays. Lumbar punctures were performed at baseline and at 1, 2, and 3–5 years post‐aHSCT. Biomarker findings were compared with standard CSF parameters, prior treatments, and MRI data. Results: MMP‐9/TIMP‐1 ratios and OPN levels were significantly elevated in pwMS compared to controls, particularly in those with gadolinium‐enhancing lesions or on first‐line therapies. Both biomarkers declined significantly after aHSCT and remained low during follow‐up. The MMP‐9/TIMP‐1 ratio showed superior discriminatory capacity and correlated with inflammatory CSF markers. Interpretation: CSF MMP‐9/TIMP‐1 ratio and OPN are elevated in MS and decrease following aHSCT, reflecting reduced inflammation and restored BBB integrity. These biomarkers may support disease monitoring and therapeutic evaluation.